Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNASDAQ:APLTNASDAQ:PLRXOTCMKTS:TRXDW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.50-3.8%$2.74$2.07▼$4.20$80.49M0.4390,041 shs42,314 shsAPLTApplied Therapeutics$0.410.0%$0.42$0.30▼$10.62$58.03M23.35 million shs1.90 million shsPLRXPliant Therapeutics$1.29-3.7%$1.43$1.10▼$16.10$79.19M1.431.10 million shs511,950 shsTRXDWTransEnterix$0.15$0.15$0.12▼$0.18$21.42M2.568,250 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-3.85%-5.66%-8.42%-18.83%-3.85%APLTApplied Therapeutics-0.02%-32.01%+10.78%-22.66%-90.19%PLRXPliant Therapeutics-3.73%-6.52%-16.23%-58.12%-90.90%TRXDWTransEnterix0.00%0.00%0.00%0.00%+13,536.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences1.7033 of 5 stars3.63.00.00.00.61.70.0APLTApplied Therapeutics3.9982 of 5 stars3.32.00.04.72.72.50.6PLRXPliant Therapeutics4.2372 of 5 stars4.02.00.04.72.61.70.6TRXDWTransEnterixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00260.00% UpsideAPLTApplied Therapeutics 2.50Moderate Buy$6.101,388.17% UpsidePLRXPliant Therapeutics 2.00Hold$13.31931.98% UpsideTRXDWTransEnterix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRXDW, APLT, ANIX, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.504/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025ANIXAnixa BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/18/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.503/4/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.003/4/2025PLRXPliant TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/4/2025PLRXPliant TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K383.30N/AN/A$0.59 per share4.24APLTApplied Therapeutics$265K218.99N/AN/A($0.20) per share-2.05PLRXPliant Therapeutics$1.58M50.12N/AN/A$7.91 per share0.16TRXDWTransEnterix$8.53M2.51$0.11 per share1.40$2.68 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.39N/A∞N/AN/A-58.55%-53.29%6/3/2025 (Estimated)APLTApplied Therapeutics-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)PLRXPliant Therapeutics-$161.34M-$3.61N/AN/AN/AN/A-48.91%-41.09%8/6/2025 (Estimated)TRXDWTransEnterix-$154.20M-$4.22N/AN/AN/A-2,149.15%-83.74%-64.94%N/ALatest TRXDW, APLT, ANIX, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/11/2025Q1 2025ANIXAnixa Biosciences-$0.10-$0.10N/A-$0.10N/AN/A3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ATRXDWTransEnterixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.548.54APLTApplied TherapeuticsN/A1.061.06PLRXPliant Therapeutics0.0910.2610.26TRXDWTransEnterix0.043.242.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%APLTApplied Therapeutics98.31%PLRXPliant Therapeutics97.30%TRXDWTransEnterix8.22%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%APLTApplied Therapeutics8.60%PLRXPliant Therapeutics8.00%TRXDWTransEnterix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.20 million24.05 millionOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionablePLRXPliant Therapeutics9061.39 million56.96 millionOptionableTRXDWTransEnterixN/A142.78 millionN/ANot OptionableTRXDW, APLT, ANIX, and PLRX HeadlinesRecent News About These CompaniesLife Science Partners L P Synergy's Net WorthFebruary 9, 2024 | benzinga.comAsensus Surgical Inc (ASXC)January 30, 2024 | investing.comTransEnterix, Inc. (TRXDW)January 21, 2024 | ca.finance.yahoo.comSurgical Robots Global Market Report 2023June 13, 2023 | finance.yahoo.comAsensus Surgical (NYSEMKT: ASXC)May 27, 2023 | fool.comProfitable Strategic Report for the Robotic Endoscopy Devices Market with Business Strategies, Current Insight - openPRMay 12, 2023 | news.google.comAsia Pacific Minimally Invasive Gastrointestinal (GI) Surgical ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comGlobal Minimally Invasive Gastrointestinal (GI) Surgical Systems ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comAsensus Surgical, Inc. Reports Operating and Financial Results for ... - BenzingaMay 12, 2023 | news.google.comSurgical Robots Market 2023 is Booming Across the Globe by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comBariatric Surgery Devices Market Size, Trends, Share, Growth and ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comSurgical Robots Market: The global market is expected to grow at a ... - Digital JournalMay 10, 2023 | news.google.comMinimally Invasive Gastrointestinal (GI) Surgical Systems Market ... - Digital JournalMay 10, 2023 | news.google.comSurgical Robots Market to Grow at Rapid Pace with Advancements ... - Digital JournalMay 10, 2023 | news.google.comMedical Intelligent Auxiliary Robot Market 2023 Competitive Insights ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comGlobal Healthcare Robotics-Surgical Robots Market 2023, CAGR ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comSurgical Robots Market Excellent CAGR of 18%, Growth, Industry ... - Digital JournalMay 8, 2023 | news.google.comExponential Growth Expected for Intelligent Tissue Autonomous Robots Market With Complete SWOT Analysis by For - openPRMay 8, 2023 | news.google.comObesity Surgery Device Market Research Report 2023-2031 Market ... - The Northwestern ExaminerMay 7, 2023 | news.google.comGlobal Surgical Robotics Market Insights Report 2022, Trends ... - FylladeyMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRXDW, APLT, ANIX, and PLRX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$2.50 -0.10 (-3.85%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.60 +0.10 (+4.00%) As of 05/23/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Applied Therapeutics NASDAQ:APLT$0.41 0.00 (-0.02%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.40 0.00 (-1.20%) As of 05/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Pliant Therapeutics NASDAQ:PLRX$1.29 -0.05 (-3.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.31 +0.02 (+1.24%) As of 05/23/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.TransEnterix OTCMKTS:TRXDW$0.15 0.00 (0.00%) As of 03/7/2025TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
